Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

The Dermatitis Family Impact questionnaire: a review of its measurement properties and clinical application

Dodington, Sean R., Basra, M. K. A., Finlay, Andrew Yule ORCID: https://orcid.org/0000-0003-2143-1646 and Salek, Mir-saeed 2013. The Dermatitis Family Impact questionnaire: a review of its measurement properties and clinical application. British Journal of Dermatology 169 (1) , pp. 31-46. 10.1111/bjd.12232

Full text not available from this repository.

Abstract

The Dermatitis Family Impact (DFI) questionnaire is a disease-specific measure to assess the impact of atopic eczema on the quality of life (QoL) of the parents and family members of affected children. We set out to review the published literature and to collate data on the clinical and psychometric aspects of the DFI questionnaire from its development in 1998–2012, in order to create a single source of reference for users of the DFI. A literature search was performed of publications, including abstracts, describing the use of the DFI between 1998 and 2012. In total, we indentified 53 publications (37 full articles and 16 abstracts) describing the use of the DFI in 50 studies. Only one study demonstrated test–retest reliability (r = 0·95). Three studies demonstrated internal consistency, with Cronbach α ranging from 0·85 to 0·90. Fifteen studies showed sensitivity to change of DFI scores, with significant differences between baseline and the end of the study. Twenty-six studies correlated the DFI to other objective and subjective instruments to demonstrate its construct (convergent) validity. Seventeen validated translations of the DFI have been used in 16 different countries (including two multinational studies). Nine clinical studies have assessed the effectiveness of five different topical drugs and one probiotic supplement. Two studies have assessed the effectiveness of care by dermatology nurses and dermatologists. The use of the DFI has revealed the major impact of atopic eczema on the QoL of families of affected children. The strengths of the DFI include wide international experience of its use, defined test–retest reliability, good internal consistency, sensitivity to change, and good construct (convergent) validity. Areas requiring further research include creation of validated score descriptors, assessment of minimum important clinical difference and testing of dimensionality, factor structure and differential item functioning.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Pharmacy
Subjects: R Medicine > RA Public aspects of medicine
R Medicine > RL Dermatology
R Medicine > RM Therapeutics. Pharmacology
Publisher: Wiley-Blackwell
ISSN: 0007-0963
Last Modified: 14 Dec 2022 03:06
URI: https://orca.cardiff.ac.uk/id/eprint/56636

Citation Data

Cited 28 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item